News · 26 weeks73-23%
2026-03-082026-08-30
Mix3790d
- Insider20(54%)
- SEC Filings8(22%)
- Earnings5(14%)
- Other4(11%)
Latest news
25 items- SECRoivant Sciences Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Roivant Sciences Ltd. (0001635088) (Filer)
- SECRoivant Sciences Ltd. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Roivant Sciences Ltd. (0001635088) (Filer)
- PRRoivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.LISRAYA represents the first major therapeutic innovation in decades for adults with dermatomyositis (DM), a debilitating systemic autoimmune diseaseLISRAYA is a once-daily pill that directly targets key immune pathways implicated in dermatomyositis pathogenesisLISRAYA demonstrated robust efficacy on multiple measures of DM disease activity, accompanied by substantial steroid-sparing benefits, in the largest dermatomyositis clinical trial ever conductedLISRAYA is available immediately in the U.S.Eligible patients may pay as little as $0 per month through the LISRAYA My Compass Support program.Roivant will host an investor call to discuss these updates tomorrow, August 28, 2026, at 8:00 a.m.
- PRPriovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.LISRAYA represents the first major therapeutic innovation in decades for adults with dermatomyositis (DM), a debilitating systemic autoimmune diseaseLISRAYA is a once-daily pill that directly targets key immune pathways implicated in dermatomyositis pathogenesisLISRAYA demonstrated robust efficacy on multiple measures of DM disease activity, accompanied by substantial steroid-sparing benefits, in the largest dermatomyositis clinical trial ever conductedLISRAYA is available immediately in the U.S.Eligible patients may pay as little as $0 per month through the LISRAYA My Compass Support program. DURHAM, N.C., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics today announced that the
- PRJAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in DermatomyositisJAMA Dermatology publication includes results from VALOR skin-specific secondary endpoints, with rapid and durable improvements seen for brepocitinib 30 mg compared to placebo across multiple dimensions of cutaneous dermatomyositis (DM), including measurements of disease activity, itch, and skin-related quality of lifeIn patients with at least moderate itch at baseline, clinically meaningful improvements were observed as early as Week 4 in 54% of brepocitinib 30 mg patients versus 10% with placebo, increasing to 74% versus 33%, respectively, by Week 52Nearly half of brepocitinib 30 mg treated patients with moderate-to-severe skin disease at baseline achieved remission-level outcomes by Week
- INSIDERCFO Pulik Richard covered exercise/tax liability with 5,749 shares, decreasing direct ownership by 2% to 271,810 units (SEC Form 4) (withholding obligation)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERPresident & Immunovant CEO Venker Eric covered exercise/tax liability with 13,909 shares, decreasing direct ownership by 0.86% to 1,599,154 units (SEC Form 4) to cover withholding tax4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERPresident & CIO Sukhatme Mayukh sold $12,360,813 worth of shares (335,174 units at $36.88) and exercised 335,174 shares at a strike of $3.85 (SEC Form 4)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERPresident & CIO Sukhatme Mayukh exercised 664,826 shares at a strike of $3.85 and sold $24,160,402 worth of shares (664,826 units at $36.34) (SEC Form 4)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Roivant Sciences Ltd.SCHEDULE 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)
- SECSEC Form 10-Q filed by Roivant Sciences Ltd.10-Q - Roivant Sciences Ltd. (0001635088) (Filer)
- SECRoivant Sciences Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Roivant Sciences Ltd. (0001635088) (Filer)
- PRRoivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business UpdateCommercial preparations for brepocitinib in dermatomyositis (DM) are progressing well and on track for launch by the end of September 2026; topline data from Phase 3 study in non-infectious uveitis (NIU) expected in the second half of calendar year 2026First patients enrolled in the Phase 3 study of brepocitinib in cutaneous sarcoidosis (CS), with topline data expected in calendar year 2028; enrollment in Part 1 of the Phase 2b/3 study in lichen planopilaris (LPP) is progressing wellIMVT-1402 proof-of-concept trial in cutaneous lupus erythematosus (CLE) topline data expected in the second half of calendar year 2026; all clinical development timelines remain on track for IMVT-1402Mosliciguat
- PRImmunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves’ disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat rheumatoid arthritis (D2T RA), Sjögren’s disease (SjD) and cutaneous lupus erythematosus (CLE)Current cash balance provides runway to the potential launch of IMVT-1402 in GDRoivant will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 6, 2026 DURHAM, N.C., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Immunovant (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate update
- PRPriovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)CS is a highly morbid, chronic, and disfiguring condition with no approved therapiesBrepocitinib is the first investigational therapy to generate a positive result in a placebo-controlled CS study (Phase 2 BEACON) and has received FDA Breakthrough Therapy Designation for CSGlobal Phase 3 study (BEACON+) is underway, evaluating brepocitinib 45 mg once daily against placebo in 140 patients across approximately 70 sites globally; BEACON+ topline data expected in calendar year 2028Brepocitinib’s development program now includes four indications with ongoing or successfully completed registrational trials: dermatomyositis (DM), non-infectious uveitis (NIU), lichen planopilaris (LPP), and CS; pote
- INSIDERPresident & Immunovant CEO Venker Eric exercised 200,000 shares at a strike of $3.85 and sold $6,990,000 worth of shares (200,000 units at $34.95) (SEC Form 4)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- SECSEC Form DEFA14A filed by Roivant Sciences Ltd.DEFA14A - Roivant Sciences Ltd. (0001635088) (Filer)
- SECSEC Form DEF 14A filed by Roivant Sciences Ltd.DEF 14A - Roivant Sciences Ltd. (0001635088) (Filer)
- PRImmunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026DURHAM, N.C., July 23, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced that it will report its financial results for the first quarter ended June 30, 2026 on Thursday, August 6, 2026 before the market opens. Roivant Sciences Ltd. (ROIV), Immunovant’s majority stockholder, will host a live conference call and webcast at 8:00 a.m. ET that same day, which will include a business update for Immunovant. To access the Roivant (NASDAQ:ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "News & Events" in the Investors section of the Immunovant website at https://www.immunov
- PRRoivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026BASEL, Switzerland and LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 6, 2026, to report its financial results for the first quarter ended June 30, 2026, and provide a business update. To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "Events & Presentations" in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant’s website after the conference call. About
- INSIDERDirector Epperly Melissa B, was granted 543 shares, increasing direct ownership by 3% to 17,017 units (SEC Form 4)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERDirector Oren Ilan was granted 775 shares, increasing direct ownership by 0.64% to 121,004 units (SEC Form 4)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERDirector Momtazee James C was granted 405 shares, increasing direct ownership by 0.37% to 109,810 units (SEC Form 4)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERCEO Gline Matthew covered exercise/tax liability with 76,171 shares, decreasing direct ownership by 0.46% to 16,659,945 units (SEC Form 4) (for withholding tax)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERDirector Fitzgerald Meghan exercised 10,000 shares at a strike of $8.80 and sold $349,000 worth of shares (10,000 units at $34.90) (SEC Form 4)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
ROIV FAQ
6 questionsWhat does Roivant Sciences Ltd. do?
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.Where does ROIV stock trade?
Roivant Sciences Ltd. (ROIV) is listed on NASDAQ.What sector and industry is ROIV in?
Roivant Sciences Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ROIV?
Roivant Sciences Ltd. has had 8 recent analyst actions on file. The most recent action was from Bernstein: Outperform with a $3500.00 price target on 2026-03-20. Recent price targets range from $1050.00 to $3500.00.What companies are similar to ROIV?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ROIV side-by-side with any of them on Quantisnow.How can I track ROIV on Quantisnow?
Quantisnow aggregates Roivant Sciences Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ROIV to receive live email and push alerts on every new disclosure.